About Non-Alcoholic Steatohepatitis (NASH)
NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH.
Technavio’s analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Non-Alcoholic Steatohepatitis (NASH) Market 2016-2020
Technavio recognizes the following companies as the key players in the global non-alcoholic steatohepatitis (NASH) market: Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, and Vivus.
Other Prominent Vendors in the market are: Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, and Viking Therapeutics.
Commenting on the report, an analyst from Technavio’s team said: “One noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons.”
According to the report, a key driver of market growth is an increasingly sedentary lifestyle. An unhealthy or sedentary lifestyle and the intake of high calorie food results in the accumulation of excess body fat, causing problems such as obesity, diabetes, cardiovascular problems, and liver disease, which are the associated conditions for NASH. This provides drug manufacturers with opportunities to manufacture new and effective drugs, thereby boosting the growth of the global NASH drugs market.
Further, the report states that one challenge that could severely impact market growth is the limited understanding of the disease’s pathophysiology.
Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, Viking Therapeutics.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook